The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Cell and Gene Therapy CROs Market by Type of Therapy (Cell Therapy (Stem Cells, Immune Cells and Others) and Gene Therapy), Scale of Operation (Drug Discovery, Preclinical, Clinical and Commercialization), Preclinical Services Offered, Clinical Services Offered, and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (2nd Edition), 2021-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    March 2021

  • Pages
    315

  • View Count
    6500

Example Insights

Cell-and-Gene-Therapy-CROs-Market-Context Cell-and-Gene-Therapy-CROs-Market-Geographical-Distribution-of-Completed-and-Active-Trials Cell-and-Gene-Therapy-CROs-Market-CROs-Market-Landscape Cell-and-Gene-Therapy-CROs-Market-Distribution-by-Type-of-Therapies
Cell-and-Gene-Therapy-CROs-Market-Benchmark-Analysis Cell-and-Gene-Therapy-CROs-Market-Partnerships-and-Collaborations Cell-and-Gene-Therapy-CROs-Market-Mergers-and-Acquisitions Cell-and-Gene-Therapy-CROs-Market-Potential-Strategic-Partners
Cell-and-Gene-Therapy-CROs-Market-Key-Evaluations-Parameters Cell-and-Gene-Therapy-CROs-Market-Market-Forecast    

 

Overview

Given their ability to treat a wide range of clinical conditions, including oncological disorders, cardiovascular disorders, genetic disorders, ophthalmic diseases and orthopedic disorders, advanced therapy medicinal products (ATMPs) have revolutionized the delivery of healthcare. Presently, over 30 cell and gene therapies have received marketing approval, while around 1,000 therapeutic leads are under evaluation. Considering the advantages of ATMPs, and their ability to address the underlying causes of several serious clinical conditions wherein small molecule drugs have been proven to be inadequate, the preference for such therapeutic modalities is on the rise. In fact, experts believe that, by 2030, 40 - 60 such products are likely to be approved in the US alone. However, as is the case for all biological products, the development of cell and gene therapies is both complex and challenging, as well as subject to heavy regulatory scrutiny. Outsourcing is, therefore, a preferred operational model in this field, with innovator companies relying heavily on specialty contract service providers to handle various aspects of their product development and manufacturing operations. 

Contract research organizations (CROs) that claim to have the necessary capabilities to facilitate cell and gene therapy-related R&D, usually have extensive experience and are well-aware of the nuances of ATMP design and development. Moreover, innovators that rely on the aforementioned CROs end up saving significant capital, which would otherwise have been spent on developing R&D infrastructure and / or expertise. Overall, engaging the services of an experienced CRO for cell and gene therapy-related R&D offers certain time-related advantages, as well, to sponsors. Over the years, several contract service providers have also formed strategic alliances and consolidated their positions in the market, by upgrading / expanding existing capabilities and collaborating with other stakeholders in order to expand their service portfolios or geographical reach. Further, CROs have made significant investments towards the development / adoption of advanced tools, technologies and platforms, in order to generate more robust and evidence based clinical data, which is required for gaining the marketing authorizations across different geographies. Given the rising trend of outsourcing in the healthcare industry and the ongoing efforts of service providers to further improve / expand their respective offerings, we believe the cell and gene therapy CRO market is likely to evolve at a steady pace, till 2030.

Scope of the Report

The “Cell and Gene Therapy CROs Market (2nd Edition), 2021-2030: Distribution by Type of Therapy (Cell Therapy and Gene Therapy), Scale of Operation (Clinical and Preclinical), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Inflammatory Disorders, Neurological Disorders, and Other Therapeutic Areas), and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World)” report features an extensive study of the current market landscape and the likely future potential of the cell and gene therapy CROs market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:

  • A detailed review of the overall landscape of the cell and gene therapy services market, highlighting the contributions of CROs, along with the information on their year of establishment, company size, location of headquarters, type of therapy (cell therapy (stem cells, T cells, dendritic cells, NK cells and tumor cells) and gene therapy), scale of operation (clinical and preclinical) and types of services offered, including [A] clinical services (clinical trial management, clinical trial monitoring, data management and project management, clinical safety and quality studies, regulatory services, consultancy services and IT / informatics services) and [B] preclinical services (bioanalytical services, toxicology studies, in vivo studies, preclinical safety and quality studies and support services). 
  • A benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies (in terms of their expertise across various services related to the development of cell and gene therapies). The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to become more competitive in the industry.  
  • A detailed analysis of the various partnerships inked between CROs offering cell and gene therapy related services, which have been established during the period 2015-2020. It includes a brief description of various types of partnerships models (such as outsourcing agreements, licensing agreements, and service alliances) that have been adopted by stakeholders engaged in this domain since 2015. 
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2015-2020. It is worth mentioning that the data captured during our research was analyzed based on several parameters, such as year, type of acquisition, geographical location of the companies, type of therapy and type of cells.
  • A detailed acquisition target analysis, taking into consideration historical trend of the activity of players that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.
  • An in-depth analysis of more than 260 cell therapy developers that are anticipated to partner with contract research organizations and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other cell therapy capabilities.
  • An in-depth analysis of nearly 190 gene therapy developers that are anticipated to partner with contract research organizations and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.
  • A detailed clinical trial analysis of ongoing clinical studies for the evaluation of various cell and gene therapy product candidates. The analysis provides details related to cell and gene therapy focused clinical studies being carried out across various geographies, based on the number of registered trials, year of trial, current trial status, current phase of development, key therapeutic areas (including indication-wise distribution), type of cell therapy (stem cells, T cells, dendritic cells, NK cells and tumor cells) and number of patients enrolled.  
  • A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall cell and gene therapies research services industry.
  • Elaborate profiles of prominent CROs engaged in offering cell and gene therapy related services. Each company profile features a brief overview of the company, along with information on their year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), service portfolio, recent developments and an informed future outlook.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the cell and gene therapy CROs market over the coming decade. We have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of therapy (cell therapy and gene therapy), [B] scale of operation (clinical and preclinical), [C] target therapeutic area (oncology and non-oncology) and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and rest of the world).  In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players: 

  • Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
  • Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players engaged in offering cell and gene therapy related research services?
  • Which business models are most commonly adopted by biopharmaceutical developers for outsourcing cell and gene therapies?
  • Which partnership models are commonly adopted by stakeholders engaged in this industry?
  • What are the key value drivers of the merger and acquisition activity in the cell and gene therapy market?
  • Which players are likely to partner with cell and gene therapy CROs? 
  • Which regions emerged as the key hubs for carrying out clinical studies focused on cell and gene therapies?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to cell and gene therapy related research services?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of cell and gene therapy CROs market and its likely evolution in the mid-long term.

Chapter 3 provides a general introduction to CROs, featuring insights on the historical evolution of such organizations, legacy and contemporary trends in outsourcing activity. It provides a brief introduction to the concept of CROs, featuring a discussion on the historical evolution of contract research services market in this domain. Additionally, it includes details on the various types of services offered by different CROs. Further, the chapter highlights advantages and risks associated in partnering with contract service providers, and their role in the development of ATMPs.

Chapter 4 provides a detailed discussion on the business models that are commonly adopted by the biopharmaceutical industry for outsourcing cell and gene therapies. In addition, it includes information on various factors that drive sponsors towards outsourcing and key parameters that sponsors must consider while choosing CROs at each phase of drug development process.

Chapter 5 provides a detailed review of the overall landscape of the cell and gene therapy services market, highlighting the contributions of CROs, along with the information on year of establishment, company size, location of headquarters, A detailed assessment of the overall market landscape of about 100 CROs offering cell and gene therapies based on a number of relevant parameters, such as  type of therapy (cell therapy (stem cells, T cells, dendritic cells, NK cells and tumor cells) and gene therapy), scale of operation (clinical and preclinical) and types of services offered including [A] clinical services (clinical trial management, clinical trial monitoring, data management and project management, clinical safety and quality studies, regulatory services, consultancy services and IT / informatics services) and [B] preclinical services (bioanalytical services, toxicology studies, in vivo studies, preclinical safety and quality studies and support services). 

Chapter 6 features elaborate profiles of prominent CROs engaged in offering cell and gene therapy related services. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters, key executives, financial details / information (if available), service portfolio, recent developments and an informed future outlook.

Chapter 7 presents a benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies (in terms of their expertise across various services related to the development of cell and gene therapies). The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to become more competitive in the industry.  

Chapter 8 features an analysis of the various partnerships inked between CROs offering cell and gene therapy related services, which have been established during the period 2015-2020. It includes a brief description of various types of partnerships models (such as outsourcing agreements, licensing agreements, and service alliances) that have been adopted by stakeholders engaged in this domain since 2015.

Chapter 9 presents insights from a detailed analysis of the various mergers and acquisitions that have taken place in this domain, during the period 2015-2020. It is worth mentioning that the data captured during our research was analyzed based on several parameters, such as year, type of acquisition, geographical location of the companies, type of therapy and type of cells.

Chapter 10 provides a detailed acquisition target analysis, taking into consideration historical trend of the activity of players that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.

Chapter 11 features an in-depth analysis of more than 260 cell therapy developers that are anticipated to partner with contract research organizations and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other cell therapy capabilities.

Chapter 12 features an in-depth analysis of more than 190 gene therapy developers that are anticipated to partner with contract research organizations and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.

Chapter 13 features a comprehensive clinical trial analysis of ongoing clinical studies for the evaluation of various cell and gene therapy product candidates. The analysis provides details related to cell and gene therapy focused clinical studies being carried out across various geographies, based on the number of registered trials, year of trial, current trial status, current phase of development, key therapeutic areas (including indication-wise distribution), type of cell therapy (stem cells, T cells, dendritic cells, NK cells and tumor cells) and number of patients enrolled.  

Chapter 14 features a comprehensive market forecast analysis, highlighting the likely growth of cell and gene therapy CROs market, for the time period 2021-2030. In order to provide details on the future outlook, our projections have been segmented on the basis of [A] type of therapy (cell therapy and gene therapy) [B] scale of operation (clinical and preclinical), [C] target therapeutic area (oncology and non-oncology) and [D] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and rest of the world).
 
Chapter 15 provides a detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall cell and gene therapies research services industry.

Chapter 16 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 17 is a collection of interview transcripts of the discussions that were held key stakeholders in the industry. The chapter provides details of interviews held with Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital) and Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado).

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 19 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION 
3.1. Chapter Overview 
3.2. Overview of Contract Research Organizations (CROs) 
3.2.1. Evolution of CROs 
3.2.2. Modern CROs and Prevalent Outsourcing Trends

3.3. Services Offered by CROs
3.4. Classification of CROs 
3.5. Advantages of Outsourcing Operations to CROs 
3.6. Risks Associated with Outsourcing to CROs 
3.7. Role of CROs in the Development of Advanced Therapy Medicinal Products (ATMPs)
3.8. Future Perspectives

4. GUIDE TO OUTSOURCING
4.1. Chapter Overview 
4.2. Outsourcing Cell and Gene Therapy Research

4.3. Guiding Models of Outsourcing 
4.3.1. Transactional Outsourcing Model 
4.3.2. Performance / Outcome-based Business Model
4.3.3. Staff Augmentation Model
4.3.4. Phase-Dependent Outsourcing Models

4.4. Selecting an Appropriate Outsourcing Model
4.4.1. Hybrid Approach

4.5. Selecting a CRO Partner
4.5.1 Key Considerations for Outsourcing Cell and Gene Therapy-related Operations

4.6. Role of CROs in Drug Development 
4.6.1. Discovery and Preclinical Research
4.6.2. Early Clinical Research
4.6.3. Clinical Research and Laboratory Services

4.7. Conclusion

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Cell and Gene Therapy CROs: Overall Market Landscape
5.2.1. Analysis by Year of Establishment, Company Size and Location of Headquarters
5.2.2. Analysis by Scale of Operation

5.3. Cell and Gene Therapy: Preclinical CROs 
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size 
5.3.3. Analysis by Location of Headquarters
5.3.4. Analysis by Type of Therapy 
5.3.4.1. Analysis by Type of Cell Therapy
5.3.5. Analysis by Types of Services Offered
5.3.6. Analysis by Number of Services 
5.3.7. Analysis by Services Offered and Type of Cell Therapy

5.4. Cell and Gene Therapy: Clinical CROs 
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Location of Headquarters
5.4.4. Analysis by Type of Therapy 
5.4.4.1. Analysis by Type of Cell Therapy
5.4.5. Analysis by Types of Services Offered
5.4.6. Analysis by Number of Services 
5.4.7. Analysis by Services Offered and Type of Cell Therapy

6. COMPANY PROFILES
6.1. Chapter Overview 
6.2. Players based in North America
6.2.1. Altasciences
6.2.1.1. Company Overview
6.2.1.2. Services Portfolio
6.2.1.3. Future Outlook

6.2.2. CATO SMS
6.2.2.1. Company Overview
6.2.2.2. Services Portfolio
6.2.2.3. Future Outlook

6.2.3. Charles River Laboratories
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Services Portfolio
6.2.3.3. Future Outlook

6.2.4. Covance
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Services Portfolio
6.2.4.4. Future Outlook

6.2.5. Creative Biolabs
6.2.5.1. Company Overview
6.2.5.2. Services Portfolio
6.2.5.3. Future Outlook

6.2.6. IQVIA
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Services Portfolio
6.2.6.4. Future Outlook

6.8.7. Medpace 
6.8.7.1. Company Overview
6.8.7.2. Financial Information
6.8.7.3. Services Portfolio
6.8.7.4. Future Outlook

6.8.8. PPD
6.8.8.1. Company Overview
6.8.8.2. Services Portfolio
6.8.8.3. Future Outlook

6.8.9. Precision for Medicine
6.8.9.1. Company Overview
6.8.9.2. Services Portfolio
6.8.9.3. Future Outlook

6.8.10. QPS
6.8.10.1. Company Overview
6.8.10.2. Services Portfolio
6.8.10.3. Future Outlook

6.3. Players based in Europe 
6.3.1. Accelera 
6.3.1.1. Company Overview
6.3.1.2. Services Portfolio
6.3.1.3. Future Outlook

6.3.2. Evotec
6.3.2.1. Company Overview
6.3.2.2. Services Portfolio
6.3.2.3. Future Outlook

6.3.3. ICON
6.3.3.1. Company Overview
6.3.3.2. Services Portfolio
6.3.3.3. Future Outlook

6.3.4. JSB Solutions 
6.3.4.1. Company Overview
6.3.4.2. Services Portfolio
6.3.4.3. Future Outlook

6.3.5. Quality Assistance 
6.3.5.1. Company Overview
6.3.5.2. Financial Information
6.3.5.3. Services Portfolio
6.3.5.4. Future Outlook

6.4. Players based in Asia-Pacific
6.4.1. CMIC Group 
6.4.1.1. Company Overview
6.4.1.2. Financial Information
6.4.1.3. Services Portfolio
6.4.1.4. Future Outlook

6.4.2. Pharmaseed 
6.4.2.1. Company Overview
6.4.2.2. Services Portfolio
6.4.2.3. Future Outlook

7. BENCHMARK ANALYSIS
7.1. Chapter Overview 
7.2. Methodology 
7.3. Benchmark Analysis: Peer Groups 
7.3.1. Peer Group I 
7.3.2. Peer Group II 
7.3.3. Peer Group III 
7.3.4. Peer Group IV 
7.3.5. Peer Group V
7.3.6. Peer Group VI
7.3.7. Peer Group VII
7.3.8. Peer Group VIII

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models

8.3. Cell and Gene Therapy CROs: Recent Partnerships and Collaborations 
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.2.1. Analysis by Year of Partnership and Type of Partnership
8.3.2.2. Analysis by Type of Partnership and Company Size

8.3.3. Analysis by Type of Therapy
8.3.3.1. Analysis by Year of Partnership and Type of Therapy
8.3.3.2. Analysis by Type of Partnership and Type of Therapy

8.3.4. Most Active Players: Analysis by Number of Partnerships
8.3.5. Regional Analysis
8.3.5.1. Intercontinental and Intracontinental Agreements

9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models

9.3. Acquisition Models
9.4. Cell and Gene Therapy CROs: Mergers and Acquisitions
9.4.1. Analysis by Year
9.4.2. Analysis by Type of Acquisition
9.4.3. Analysis by Geography
9.4.3.1. Continent-Wise Distribution
9.4.3.2. Country-Wise Distribution
9.4.4. Intercontinental and Intracontinental Deals
9.4.5. Analysis by Key Value Drivers
9.4.6. Valuation Analysis: Acquisition Deal Multiples
9.4.7. Most Active Players: Analysis by Number of Acquisitions

10. KEY ACQUISITION TARGETS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Scoring Criteria and Key Assumptions
10.4. Potential Strategic Acquisition Targets for Mid-sized Players
10.5. Potential Strategic Acquisition Targets for Large Players
10.6. Potential Strategic Acquisition Targets for Very Large Players
10.7. Potential Strategic Acquisition Targets for Small Players
10.8. Concluding Remarks

11. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CROs
11.1. Chapter Overview
11.2. Scope and Methodology

11.3. Potential Strategic Partners for Cell Therapy CROs
11.3.1. Likely Partner Opportunities for Stem Cell Therapy CROs
11.3.2. Likely Partner Opportunities for CAR-T Therapy CROs
11.3.3. Likely Partner Opportunities for Dendritic Cell Therapy CROs
11.3.4. Likely Partner Opportunities for Tumor Cell Therapy CROs
11.3.5. Likely Partner Opportunities for NK Cell Therapy CROs

12. LIKELY PARTNER ANALYSIS FOR GENE THERAPY CROs
12.1. Chapter Overview
12.2. Scope and Methodology

12.3. Potential Strategic Partners for Gene Therapy CROs 
12.3.1. Likely Partner Opportunities in North America
12.3.2. Likely Partner Opportunities in Europe
12.3.3. Likely Partner Opportunities in Asia-Pacific

13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Cell Therapies: Analysis by Number of Clinical Trials
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Status
13.3.3. Analysis by Phase of Development
13.3.4. Analysis by Target Therapeutic Area
13.3.5. Analysis by Type of Sponsor
13.3.6. Analysis by Prominent Treatment Sites
13.3.7. Analysis by Geography
13.3.8. Analysis by Trial Registration Year and Geography
13.3.9. Analysis by Trial Status and Geography
13.3.10. Analysis by Trial Status, Trial Phase and Geography
13.3.11. Analysis by Therapeutic Area and Geography

13.4. Cell Therapies: Analysis by Enrolled Patient Population
13.4.1. Analysis by Trial Registration Year
13.4.2. Analysis by Trial Status
13.4.3. Analysis by Trial Phase
13.4.4. Analysis by Target Therapeutic Area
13.4.5. Analysis by Location of Trial Site
13.4.6. Analysis by Trial Status and Location of Trial Site
13.4.7. Analysis by Trial Status, Trial Phase and Location of Trial Site
13.4.8. Analysis by Therapeutic Area and Location of Trial Site

13.5. Gene Therapies: Analysis by Clinical Trials
13.5.1. Analysis by Trial Registration Year
13.5.2. Analysis by Trial Status
13.5.3. Analysis by Phase of Development
13.5.4. Analysis by Target Therapeutic Area
13.5.5. Analysis by Type of Sponsor
13.5.6. Analysis by Prominent Treatment Sites
13.5.7. Analysis by Geography
13.5.8. Analysis by Trial Registration Year and Geography
13.5.9. Analysis by Trial Status and Geography
13.5.10. Analysis by Trial Status, Trial Phase and Geography
13.5.11. Analysis by Therapeutic Area and Geography

13.6. Gene Therapy Clinical Trials: Analysis by Patients Enrolled
13.6.1. Analysis by Trial Registration Year
13.6.2. Analysis by Trial Status
13.6.3. Analysis by Trial Phase
13.6.4. Analysis by Therapeutic Area
13.6.5. Analysis by Location of Trial Site
13.6.6. Analysis by Trial Status and Location of Trial Site
13.6.7. Analysis by Trial Status, Trial Phase and Location of Trial Site
13.6.8. Analysis by Therapeutic Area and Location of Trial Site

14. MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Cell and Gene Therapy CROs Market
14.3.1. Global Cell and Gene Therapy CROs Market: Distribution by Type of Therapy
14.3.2. Global Cell and Gene Therapy CROs Market: Distribution by Scale of Operation
14.3.3. Global Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area
14.3.4. Global Cell and Gene Therapy CROs Market: Distribution by Geography

14.4. Cell Therapy CROs Market in North America
14.4.1. Cell Therapy CROs Market in North America: Distribution by Therapeutic Area
14.4.1.1. Cell Therapy CROs Market for Oncological Disorders in North America, 2020-2030
14.4.1.2. Cell Therapy CROs Market for Cardiovascular Disorders in North America, 2020-2030
14.4.1.3. Cell Therapy CROs Market for Inflammatory Disorders in North America, 2020-2030
14.4.1.4. Cell Therapy CROs Market for Neurological Disorders in North America, 2020-2030
14.4.1.5. Cell Therapy CROs Market for Other Therapeutic Areas in North America, 2020-2030
14.4.2. Cell Therapy CROs Market in North America: Distribution by Scale of Operation
14.4.2.1. Cell Therapy CROs Market for Clinical Operations in North America, 2020-2030
14.4.2.2. Cell Therapy CROs Market for Preclinical Operations in North America, 2020-2030

14.5. Cell Therapy CROs Market in Europe
14.5.1. Cell Therapy CROs Market in Europe: Distribution by Therapeutic Area
14.5.1.1. Cell Therapy CROs Market for Oncological Disorders in Europe, 2020-2030
14.5.1.2. Cell Therapy CROs Market for Cardiovascular Disorders in Europe, 2020-2030
14.5.1.3. Cell Therapy CROs Market for Inflammatory Disorders in Europe, 2020-2030
14.5.1.4. Cell Therapy CROs Market for Neurological Disorders in Europe, 2020-2030
14.5.1.5. Cell Therapy CROs Market for Other Therapeutic Areas in Europe, 2020-2030
14.5.2. Cell Therapy CROs Market in Europe: Distribution by Scale of Operation
14.5.2.1. Cell Therapy CROs Market for Clinical Operations in Europe, 2020-2030
14.5.2.2. Cell Therapy CROs Market for Preclinical Operations in Europe, 2020-2030

14.6. Cell Therapy CROs Market in Asia-Pacific
14.6.1. Cell Therapy CROs Market in Asia-Pacific: Distribution by Therapeutic Area
14.6.1.1. Cell Therapy CROs Market for Oncological Disorders in Asia-Pacific, 2020-2030
14.6.1.2. Cell Therapy CROs Market for Cardiovascular Disorders in Asia-Pacific, 2020-2030
14.6.1.3. Cell Therapy CROs Market for Inflammatory Disorders in Asia-Pacific, 2020-2030
14.6.1.4. Cell Therapy CROs Market for Neurological Disorders in Asia-Pacific, 2020-2030
14.6.1.5. Cell Therapy CROs Market for Other Therapeutic Areas in Asia-Pacific, 2020-2030
14.6.2. Cell Therapy CROs Market in Asia-Pacific: Distribution by Scale of Operation
14.6.2.1. Cell Therapy CROs Market for Clinical Operations in Asia-Pacific, 2020-2030
14.6.2.2. Cell Therapy CROs Market for Preclinical Operations in Asia-Pacific, 2020-2030

14.7. Cell Therapy CROs Market in Latin America
14.8. Cell Therapy CROs Market in Middle East North America
14.9. Cell Therapy CROs Market in Rest of the World

14.10. Gene Therapy CROs Market in North America
14.10.1. Gene Therapy CROs Market in North America: Distribution by Therapeutic Area
14.10.1.1. Gene Therapy CROs Market for Oncological Disorders in North America, 2020-2030
14.10.1.2. Gene Therapy CROs Market for Cardiovascular Disorders in North America, 2020-2030
14.10.1.3. Gene Therapy CROs Market for Inflammatory Disorders in North America, 2020-2030
14.10.1.4. Gene Therapy CROs Market for Neurological Disorders in North America, 2020-2030
14.10.1.5. Gene Therapy CROs Market for Other Therapeutic Areas in North America, 2020-2030
14.10.2. Gene Therapy CROs Market in North America: Distribution by Scale of Operation
14.10.2.1. Gene Therapy CROs Market for Clinical Operations in North America, 2020-2030
14.10.2.2. Gene Therapy CROs Market for Preclinical Operations in North America, 2020-2030

14.11. Gene Therapy CROs Market in Europe
14.11.1. Gene Therapy CROs Market in Europe: Distribution by Therapeutic Area
14.11.1.1. Gene Therapy CROs Market for Oncological Disorders in Europe, 2020-2030
14.11.1.2. Gene Therapy CROs Market for Cardiovascular Disorders in Europe, 2020-2030
14.11.1.3. Gene Therapy CROs Market for Inflammatory Disorders in Europe, 2020-2030
14.11.1.4. Gene Therapy CROs Market for Neurological Disorders in Europe, 2020-2030
14.11.1.5. Gene Therapy CROs Market for Other Therapeutic Areas in Europe, 2020-2030
14.11.2. Gene Therapy CROs Market in Europe: Distribution by Scale of Operation
14.11.2.1. Gene Therapy CROs Market for Clinical Operations in Europe, 2020-2030
14.11.2.2. Gene Therapy CROs Market for Preclinical Operations in Europe, 2020-2030

14.12. Gene Therapy CROs Market in Asia-Pacific
14.12.1. Gene Therapy CROs Market in Asia-Pacific: Distribution by Therapeutic Area
14.12.1.1. Gene Therapy CROs Market for Oncological Disorders in Asia-Pacific, 2020-2030
14.12.1.2. Gene Therapy CROs Market for Cardiovascular Disorders in Asia-Pacific, 2020-2030
14.12.1.3. Gene Therapy CROs Market for Inflammatory Disorders in Asia-Pacific, 2020-2030
14.12.1.4. Gene Therapy CROs Market for Neurological Disorders in Asia-Pacific, 2020-2030
14.12.1.5. Gene Therapy CROs Market for Other Therapeutic Areas in Asia-Pacific, 2020-2030
14.12.2. Gene Therapy CROs Market in Asia-Pacific: Distribution by Scale of Operation
14.12.2.1. Gene Therapy CROs Market for Clinical Operations in Asia-Pacific, 2020-2030
14.12.2.2. Gene Therapy CROs Market for Preclinical Operations in Asia-Pacific, 2020-2030

14.13. Gene Therapy CROs Market in Latin America
14.14. Gene Therapy CROs Market in Middle East North America
14.15. Gene Therapy CROs Market in Rest of the World

14.16. Concluding Remarks

15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Strengths
15.3. Weaknesses
15.4. Opportunities
15.5. Threats
15.6. Comparison of SWOT Factors

16. CONCLUSION

17. INTERVIEW AND SURVEY TRANSCRIPTS
17.1. Chapter Overview
17.2. CATO SMS
17.2.1. Company Snapshot
17.2.2. Survey Transcript: Jessica Bliven, Director, Marketing and Sales

17.3. Diamond Pharma Services
17.3.1. Company Snapshot
17.3.2. Survey Transcript: Roley Davis, Business Development Manager

17.4. Changhai Hospital, Second Military Medical University
17.4.1. University Snapshot
17.4.2. Survey Transcript: Xian-Bao Zhan, Professor of Medicine, Director, Department of Oncology

17.5. University of Colorado
17.5.1. University Snapshot
17.5.2. Survey Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

18. APPENDIX I: TABULATED DATA

19. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Stages of the Drug Development Process
Figure 3.2 Services Offered by CROs
Figure 3.3 Advantages of Outsourcing Operations to CROs
Figure 3.4 Risks Associated with Outsourcing to CROs
Figure 3.5 Classification of ATMPs
Figure 3.6 Types of Cells Incorporated in Cell Therapy Medicinal Products (CTMPs)
Figure 4.1 Guiding Models of Outsourcing
Figure 4.2 Key Characteristics of Transactional Outsourcing Model
Figure 4.3 Key Characteristics of Performance / Outcome-based Business Model
Figure 4.5 Key Considerations for Selecting a CRO Partner
Figure 4.6 Role of CROs Across Different Phases of Drug Development
Figure 5.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 5.2 Cell and Gene Therapy CROs: Distribution by Scale of Operation
Figure 5.3 Cell and Gene Therapy Preclinical CROs: Distribution by Year of Establishment
Figure 5.4 Cell and Gene Therapy Preclinical CROs: Distribution by Company Size
Figure 5.5 Cell and Gene Therapy Preclinical CROs Distribution by Location of Headquarters
Figure 5.6 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Therapies
Figure 5.7 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Cell Therapies
Figure 5.8 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Services Offered
Figure 5.9 Cell and Gene Therapy Preclinical CROs: Distribution by Number of Services Offered
Figure 5.10 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Services Offered and Types of Therapies
Figure 5.11 Cell and Gene Therapy Clinical CROs: Distribution by Year of Establishment
Figure 5.12 Cell and Gene Therapy Clinical CROs: Distribution by Company Size
Figure 5.13 Cell and Gene Therapy Clinical CROs: Distribution by Location of Headquarters
Figure 5.14 Cell and Gene Therapy Clinical CROs: Distribution by Types of Therapies
Figure 5.15 Cell and Gene Therapy Clinical CROs: Distribution by Types of Cell Therapies
Figure 5.16 Cell and Gene Therapy Clinical CROs: Distribution by Types of Services Offered
Figure 5.17 Cell and Gene Therapy Clinical CROs: Distribution by Number of Services Offered
Figure 5.18 Cell and Gene Therapy Clinical CROs: Distribution by Type of Services Offered and Type of Therapies
Figure 6.1 Altasciences: Services Portfolio
Figure 6.2 CATO SMS: Services Portfolio
Figure 6.3 Charles River Laboratories: Annual Revenues, 2015-2020 (USD Billion)
Figure 6.4 Charles River Laboratories: Services Portfolio
Figure 6.5 Covance: Annual Revenues, 2015 - 9M 2020 (USD Billion)
Figure 6.6 Covance: Non-clinical Services Portfolio
Figure 6.7 Covance: Clinical Services Portfolio
Figure 6.8 Creative Biolabs: Services Portfolio for CAR-T Therapy Development
Figure 6.9 Creative Biolabs: Services Portfolio for TCR Therapy Development
Figure 6.10 IQVIA: Annual Revenues, 2015-2020 (USD Billion)
Figure 6.11 IQVIA: Distribution of Annual Revenue by Operating Business Segments (2019)
Figure 6.12 IQVIA: Services Portfolio
Figure 6.13 Medpace: Annual Revenues, 2015-2020 (USD Million)
Figure 6.14 Medpace: Services Portfolio
Figure 6.15 Medpace: Regulatory Affair Capabilities
Figure 6.16 PPD: Services Portfolio
Figure 6.17 Precision for Medicine: Services Portfolio
Figure 6.18 QPS: Services Portfolio
Figure 6.19 Accelera: Areas of Expertise
Figure 6.20 Evotec: Areas of Expertise
Figure 6.21 ICON: Services Portfolio
Figure 6.22 JSB Solutions: Services Portfolio
Figure 6.23 Quality Assistance: Annual Revenues, 2015-2019 (EUR Million)
Figure 6.24 Quality Assistance: Services Portfolio
Figure 6.25 CMIC Group: Annual Revenues, 2015-9M 2020 (JPY Billion)
Figure 6.26 CMIC Group: Non-clinical Services Portfolio
Figure 6.27 CMIC Group: Clinical Services Portfolio
Figure 6.28 Pharmaseed: Services Portfolio
Figure 7.1 Benchmark Analysis: Distribution by Location of Headquarter and Company Size
Figure 7.2 Benchmark Analysis: Peer Group I
Figure 7.3 Benchmark Analysis: Peer Group II
Figure 7.4 Benchmark Analysis: Peer Group III
Figure 7.5 Benchmark Analysis: Peer Group IV
Figure 7.6 Benchmark Analysis: Peer Group V
Figure 7.7 Benchmark Analysis: Peer Group VI
Figure 7.8 Benchmark Analysis: Peer Group VII
Figure 7.9 Benchmark Analysis: Peer Group VIII
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 8.5 Partnerships and Collaborations: Distribution by Types of Therapies
Figure 8.6 Partnerships and Collaborations: Distribution by Year of Partnership and Types of Therapies
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partnership and Types of Therapies
Figure 8.8 Most Active Players: Distribution by Number of Partnerships
Figure 8.9 Partnerships and Collaborations: Continent-Wise Distribution
Figure 8.10 Partnerships and Collaborations: Country-Wise Distribution
Figure 9.1 Mergers and Acquisitions: Distribution by Year
Figure 9.2 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 9.3 Mergers and Acquisitions: Continent-Wise Distribution
Figure 9.4 Mergers and Acquisitions: Country-Wise Distribution
Figure 9.5 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Figure 9.6 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 9.7 Valuation Analysis: Distribution by Acquisition Deal Multiples
Figure 9.8 Most Active Players: Distribution by Number of Acquisitions
Figure 13.1 Clinical Trial Analysis: Scope and Methodology
Figure 13.2 Clinical Trial Analysis for Cell Therapies: Distribution by Number of Clinical Trials
Figure 13.3 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Figure 13.4 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Figure 13.5 Clinical Trial Analysis for Cell Therapies: Distribution by Phase of Development
Figure 13.6 Clinical Trial Analysis for Cell Therapies: Distribution by Target Therapeutic Area
Figure 13.7 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor
Figure 13.8 Clinical Trial Analysis for Cell Therapies: Distribution by Prominent Treatment Sites
Figure 13.9 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Site
Figure 13.10 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year and Geography
Figure 13.11 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status and Geography
Figure 13.12 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status, Trial Phase and Geography
Figure 13.13 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area and Geography
Figure 13.14 Clinical Trial Analysis for Cell Therapies: Distribution by Enrolled Patient Population
Figure 13.15 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Figure 13.16 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Figure 13.17 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
Figure 13.18 Clinical Trial Analysis for Cell Therapies: Distribution by Target Therapeutic Area
Figure 13.19 Clinical Trial Analysis for Cell Therapies: Distribution by Enrolled Patient Population and Location of Trial Site
Figure 13.20 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status and Location of Trial Site
Figure 13.21 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status, Trial Phase and Location of Trial Site
Figure 13.22 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area and Location of Trial Site
Figure 13.23 Clinical Trial Analysis for Gene Therapies: Distribution by Number of Clinical Trials
Figure 13.24 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Figure 13.25 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Figure 13.26 Clinical Trial Analysis for Gene Therapies: Distribution by Phase of Development
Figure 13.27 Clinical Trial Analysis for Gene Therapies: Distribution by Target Therapeutic Area
Figure 13.28 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor
Figure 13.29 Clinical Trial Analysis for Gene Therapies: Distribution by Prominent Treatment Sites
Figure 13.30 Clinical Trial Analysis for Gene Therapies: Distribution by Location of Trial Site
Figure 13.31 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year and Geography
Figure 13.32 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status and Geography
Figure 13.33 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status, Trial Phase and Geography
Figure 13.34 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area and Geography
Figure 13.35 Clinical Trial Analysis for Gene Therapies: Distribution by Enrolled Patient Population
Figure 13.36 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Figure 13.37 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Figure 13.38 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
Figure 13.39 Clinical Trial Analysis for Gene Therapies: Distribution by Target Therapeutic Area
Figure 13.40 Clinical Trial Analysis for Gene Therapies: Distribution by Enrolled Patient Population and Location of Trial Site
Figure 13.41 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status and Location of Trial Site
Figure 13.42 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status, Trial Phase and Location of Trial Site
Figure 13.43 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area and Location of Trial Site
Figure 14.1 Cell and Gene Therapy CROs: Market Forecast Methodology
Figure 14.2 Global Cell and Gene Therapy CROs Market, 2021-2030
Figure 14.3 Global Cell and Gene Therapy CROs Market: Distribution by Type of Therapy, 2021 and 2030
Figure 14.4 Global Cell and Gene Therapy CROs Market: Distribution by Scale of Operation, 2021 and 2030
Figure 14.5 Global Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area, 2021 and 2030
Figure 14.6 Global Cell and Gene Therapy CROs Market: Distribution by Geography, 2021 and 2030
Figure 14.7 Cell Therapy CROs Market in North America, 2021-2030 (USD Million)
Figure 14.8 Cell Therapy CROs Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Figure 14.9 Cell Therapy CROs Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Figure 14.10 Cell Therapy CROs Market for Inflammatory Disorders in North America, 2021-2030 (USD Million)
Figure 14.11 Cell Therapy CROs Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Figure 14.12 Cell Therapy CROs Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Figure 14.13 Cell Therapy CROs Market for Clinical Operations in North America, 2021-2030 (USD Million)
Figure 14.14 Cell Therapy CROs Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Figure 14.15 Cell Therapy CROs Market in Europe, 2021-2030 (USD Million)
Figure 14.16 Cell Therapy CROs Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Figure 14.17 Cell Therapy CROs Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Figure 14.18 Cell Therapy CROs Market for Inflammatory Disorders in Europe, 2021-2030 (USD Million)
Figure 14.19 Cell Therapy CROs Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Figure 14.20 Cell Therapy CROs Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Figure 14.21 Cell Therapy CROs Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Figure 14.22 Cell Therapy CROs Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Figure 14.23 Cell Therapy CROs Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.24 Cell Therapy CROs Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.25 Cell Therapy CROs Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.26 Cell Therapy CROs Market for Inflammatory Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.27 Cell Therapy CROs Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.28 Cell Therapy CROs Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.29 Cell Therapy CROs Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.30 Cell Therapy CROs Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.31 Cell Therapy CROs Market in Latin America, 2021-2030 (USD Million)
Figure 14.32 Cell Therapy CROs Market in Middle East North America, 2021-2030 (USD Million)
Figure 14.33 Cell Therapy CROs Market in Rest of the World, 2021-2030 (USD Million)
Figure 14.34 Cell Therapy CROs Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Figure 14.35 Gene Therapy CROs Market in North America, 2021-2030 (USD Million)
Figure 14.36 Gene Therapy CROs Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Figure 14.37 Gene Therapy CROs Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Figure 14.38 Gene Therapy CROs Market for Inflammatory Disorders in North America, 2021-2030 (USD Million)
Figure 14.39 Gene Therapy CROs Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Figure 14.40 Gene Therapy CROs Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Figure 14.41 Gene Therapy CROs Market for Clinical Operations in North America, 2021-2030 (USD Million)
Figure 14.42 Gene Therapy CROs Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Figure 14.43 Gene Therapy CROs Market in Europe, 2021-2030 (USD Million)
Figure 14.44 Gene Therapy CROs Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Figure 14.45 Gene Therapy CROs Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Figure 14.46 Gene Therapy CROs Market for Inflammatory Disorders in Europe, 2021-2030 (USD Million)
Figure 14.47 Gene Therapy CROs Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Figure 14.48 Gene Therapy CROs Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Figure 14.49 Gene Therapy CROs Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Figure 14.50 Gene Therapy CROs Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Figure 14.51 Gene Therapy CROs Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.52 Gene Therapy CROs Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.53 Gene Therapy CROs Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.54 Gene Therapy CROs Market for Inflammatory Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.55 Gene Therapy CROs Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.56 Gene Therapy CROs Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.57 Gene Therapy CROs Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.58 Gene Therapy CROs Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.59 Gene Therapy CROs Market in Latin America, 2021-2030 (USD Million)
Figure 14.60 Gene Therapy CROs Market in Middle East North America, 2021-2030 (USD Million)
Figure 14.61 Gene Therapy CROs Market in Rest of the World, 2021-2030 (USD Million)
Figure 14.62 Gene Therapy CROs Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Figure 15.1 Cell and Gene Therapy CROs SWOT Analysis: Overview
Figure 15.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Concluding Remarks: Current Market Landscape for Preclinical Cell and Gene Therapy CROs
Figure 16.2 Concluding Remarks: Current Market Landscape for Clinical Cell and Gene Therapy CROs
Figure 16.3 Concluding Remarks: Recent Partnerships
Figure 16.4 Concluding Remarks: Mergers and Acquisitions
Figure 16.5 Concluding Remarks: Clinical Trial Analysis
Figure 16.6 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 List of Approved ATMP Products
Table 4.1 Attributes of Transactional Outsourcing-based Business Model
Table 5.1 Cell and Gene Therapy CROs Offering Preclinical Services: Information on Year of Establishment, Location of Headquarters, Company Size and Types of Therapies
Table 5.2 Cell and Gene Therapy CROs Offering Preclinical Services: Information on Types of Preclinical Services Offered
Table 5.3 Cell and Gene Therapy CROs Offering Clinical Services: Information on Year of Establishment, Location of Headquarters, Company Size, Types of Therapies
Table 5.4 Cell and Gene Therapy CROs Offering Clinical Services: Information on Types of Clinical Services Offered
Table 5.5 Cell and Gene Therapy CROs: Information on Regulatory Accreditations Received
Table 6.1 Altasciences: Company Overview
Table 6.2 Altasciences: Future Outlook
Table 6.3 CATO SMS: Company Overview
Table 6.4 CATO SMS: Future Outlook
Table 6.5 Charles River Laboratories: Company Overview
Table 6.6 Charles River Laboratories: Future Outlook
Table 6.7 Covance: Company Overview
Table 6.8 Covance: Future Outlook
Table 6.9 Creative Biolabs: Company Overview
Table 6.10 IQVIA: Company Overview
Table 6.11 IQVIA: Future Outlook
Table 6.12 Medpace: Company Overview
Table 6.13 Medpace: Future Outlook
Table 6.14 PPD: Company Overview
Table 6.15 PPD: Future Outlook
Table 6.16 Precision for Medicine: Company Overview
Table 6.17 Precision for Medicine: Future Outlook
Table 6.18 QPS: Company Overview
Table 6.19 QPS: Future Outlook
Table 6.20 Accelera: Company Overview
Table 6.21 Evotec: Company Overview
Table 6.22 Evotec: Future Outlook
Table 6.23 ICON: Company Overview
Table 6.24 ICON: Future Outlook
Table 6.25 JSB Solutions: Company Overview
Table 6.26 Quality Assistance: Company Overview
Table 6.27 CMIC Group: Company Overview
Table 6.28 CMIC Group: Future Outlook
Table 6.29 Pharmaseed: Company Overview
Table 7.1 Benchmark Analysis: Peer Groups
Table 8.1 Partnerships and Collaborations: Information on Partner, Year of Partnership, Type of Partnership and Types of Therapies, 2015-2020
Table 9.1 Cell and Gene Therapy CROs: List of Mergers and Acquisitions, 2015–2020
Table 9.2 Cell and Gene Therapy CROs Mergers and Acquisitions: Information on Key Value Drivers and Type of Therapy, 2015 - 2020
Table 10.1 Potential Strategic Acquisition Targets: Mid-size Players
Table 10.2 Potential Strategic Acquisition Targets: Large Players
Table 10.3 Potential Strategic Acquisition Targets: Very Large Players
Table 10.4 Potential Strategic Acquisition Targets: Small Players
Table 11.1 Likely Partners for Stem Cell Therapy CROs
Table 11.2 Likely Partners for CAR-T Therapy CROs
Table 11.3 Likely Partners for Dendritic Cell Therapy CROs
Table 11.4 Likely Partners for Tumor Cell Therapy CROs
Table 11.5 Likely Partners for NK Cell Therapy CROs
Table 12.1 Likely Partner Opportunities for Gene Therapy in North America
Table 12.2 Likely Partner Opportunities for Gene Therapy in Europe
Table 12.3 Likely Partner Opportunities for Gene Therapy in Asia-Pacific
Table 13.1 Clinical Trial Analysis: Emerging Molecules
Table 13.2 Clinical Trial Analysis: Most Important Trials
Table 17.1 CATO SMS: Company Snapshot
Table 17.2 Changhai Hospital, Second Military Medical University: University Snapshot
Table 17.3 University of Colorado: University Snapshot
Table 18.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
Table 18.2 Cell and Gene Therapy CROs: Distribution by Scale of Operation
Table 18.3 Cell and Gene Therapy Preclinical CROs: Distribution by Year of Establishment
Table 18.4 Cell and Gene Therapy Preclinical CROs: Distribution by Company Size
Table 18.5 Cell and Gene Therapy Preclinical CROs: Distribution by Location of Headquarters
Table 18.6 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Therapies
Table 18.7 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Cell Therapies
Table 18.8 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Services Offered
Table 18.9 Cell and Gene Therapy Preclinical CROs: Distribution by Number of Services Offered
Table 18.10 Cell and Gene Therapy Preclinical CROs: Distribution by Types of Services Offered and Types of Therapies
Table 18.11 Cell and Gene Therapy Clinical CROs: Distribution by Year of Establishment
Table 18.12 Cell and Gene Therapy Clinical CROs: Distribution by Company Size
Table 18.13 Cell and Gene Therapy Clinical CROs: Distribution by Location of Headquarters
Table 18.14 Cell and Gene Therapy Clinical CROs: Distribution by Types of Therapies
Table 18.15 Cell and Gene Therapy Clinical CROs: Distribution by Types of Cell Therapies
Table 18.16 Cell and Gene Therapy Clinical CROs: Distribution by Types of Services Offered
Table 18.17 Cell and Gene Therapy Clinical CROs: Distribution by Number of Services Offered
Table 18.18 Cell and Gene Therapy Clinical CROs: Distribution by Types of Services Offered and Type of Therapies
Table 18.19 Charles River Laboratories: Annual Revenues, 2015-9M 2020 (USD Billion)
Table 18.20 Covance: Annual Revenues, 2015-Q3 2020 (USD Billion)
Table 18.21 IQVIA: Annual Revenues, 2015-2020 (USD Billion)
Table 18.22 IQVIA: Distribution of Annual Revenue by Operating Business Segments (2019)
Table 18.23 Medpace: Annual Revenues, 2015-2020 (USD Million)
Table 18.24 Quality Assistance: Annual Revenues, 2015 – 2019 (EUR Million)
Table 18.25 CMIC Group: Annual Revenues, 2015-9M 2020 (JPY Billion)
Table 18.26 Partnerships and Collaborations: Distribution by Year of Partnership
Table 18.27 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.28 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 18.29 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 18.30 Partnerships and Collaborations: Distribution by Types of Therapies
Table 18.31 Partnerships and Collaborations: Distribution by Year of Partnership and Types of Therapies
Table 18.32 Partnerships and Collaborations: Distribution by Type of Partnership and Types of Therapies
Table 18.33 Most Active Players: Distribution by Number of Partnerships
Table 18.34 Partnerships and Collaborations: Continent-Wise Distribution
Table 18.35 Partnerships and Collaborations: Country-Wise Distribution
Table 18.36 Mergers and Acquisitions: Distribution by Year
Table 18.37 Mergers and Acquisitions: Distribution by Type of Acquisition
Table 18.38 Mergers and Acquisitions: Continent-Wise Distribution
Table 18.39 Mergers and Acquisitions: Country-Wise Distribution
Table 18.40 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Table 18.41 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 18.42 Valuation Analysis: Distribution by Deal Multiples
Table 18.43 Most Active Players: Distribution by Number of Acquisitions
Table 18.44 Clinical Trial Analysis for Cell Therapies: Distribution by Number of Clinical Trials
Table 18.45 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Table 18.46 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Table 18.47 Clinical Trial Analysis for Cell Therapies: Distribution by Phase of Development
Table 18.48 Clinical Trial Analysis for Cell Therapies: Distribution by Target Therapeutic Area
Table 18.49 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor
Table 18.50 Clinical Trial Analysis for Cell Therapies: Distribution by Prominent Treatment Sites
Table 18.51 Clinical Trial Analysis for Cell Therapies: Distribution by Geography
Table 18.52 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year and Geography
Table 18.53 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status and Geography
Table 18.54 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status, Trial Phase and Geography
Table 18.55 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area and Geography
Table 18.56 Clinical Trial Analysis for Cell Therapies: Distribution by Enrolled Patient Population
Table 18.57 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year
Table 18.58 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Table 18.59 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
Table 18.60 Clinical Trial Analysis for Cell Therapies: Distribution by Target Therapeutic Area
Table 18.61 Clinical Trial Analysis for Cell Therapies: Distribution by Location of Trial Site
Table 18.62 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status and Location of Trial Site
Table 18.63 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status, Trial Phase and Location of Trial Site
Table 18.64 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area and Location of Trial Site
Table 18.65 Clinical Trial Analysis for Gene Therapies: Distribution by Number of Clinical Trials
Table 18.66 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Table 18.67 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Table 18.68 Clinical Trial Analysis for Gene Therapies: Distribution by Phase of Development
Table 18.69 Clinical Trial Analysis for Gene Therapies: Distribution by Target Therapeutic Area
Table 18.70 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor
Table 18.71 Clinical Trial Analysis for Gene Therapies: Distribution by Prominent Treatment Sites
Table 18.72 Clinical Trial Analysis for Gene Therapies: Distribution by Geography
Table 18.73 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year and Geography
Table 18.74 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status and Geography
Table 18.75 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status, Trial Phase and Geography
Table 18.76 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area and Geography
Table 18.77 Clinical Trial Analysis for Gene Therapies: Distribution by Enrolled Patient Population
Table 18.78 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year
Table 18.79 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Table 18.80 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
Table 18.81 Clinical Trial Analysis for Gene Therapies: Distribution by Target Therapeutic Area
Table 18.82 Clinical Trial Analysis for Gene Therapies: Distribution by Location of Trial Site
Table 18.83 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status and Location of Trial Site
Table 18.84 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status, Trial Phase and Location of Trial Site
Table 18.85 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area and Location of Trial Site
Table 18.86 Global Cell and Gene Therapy CROs Market, 2021-2030
Table 18.87 Global Cell and Gene Therapy CROs Market: Distribution by Type of Therapy, 2021 and 2030
Table 18.88 Global Cell and Gene Therapy CROs Market: Distribution by Scale of Operation, 2021 and 2030
Table 18.89 Global Cell and Gene Therapy CROs Market: Distribution by Therapeutic Area, 2021 and 2030
Table 18.90 Global Cell and Gene Therapy CROs Market: Distribution by Geography, 2021 and 2030
Table 18.91 Cell Therapy CROs Market in North America, 2021-2030 (USD Million)
Table 18.92 Cell Therapy CROs Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Table 18.93 Cell Therapy CROs Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Table 18.94 Cell Therapy CROs Market for Inflammatory Disorders in North America, 2021-2030 (USD Million)
Table 18.95 Cell Therapy CROs Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Table 18.96 Cell Therapy CROs Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Table 18.97 Cell Therapy CROs Market for Clinical Operations in North America, 2021-2030 (USD Million)
Table 18.98 Cell Therapy CROs Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Table 18.99 Cell Therapy CROs Market in Europe, 2021-2030 (USD Million)
Table 18.100 Cell Therapy CROs Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Table 18.101 Cell Therapy CROs Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Table 18.102 Cell Therapy CROs Market for Inflammatory Disorders in Europe, 2021-2030 (USD Million)
Table 18.103 Cell Therapy CROs Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Table 18.104 Cell Therapy CROs Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Table 18.105 Cell Therapy CROs Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Table 18.106 Cell Therapy CROs Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Table 18.107 Cell Therapy CROs Market in Asia-Pacific, 2021-2030 (USD Million)
Table 18.108 Cell Therapy CROs Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.109 Cell Therapy CROs Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.110 Cell Therapy CROs Market for Inflammatory Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.111 Cell Therapy CROs Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.112 Cell Therapy CROs Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Table 18.113 Cell Therapy CROs Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 18.114 Cell Therapy CROs Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 18.115 Cell Therapy CROs Market in Latin America, 2021-2030 (USD Million)
Table 18.116 Cell Therapy CROs Market in Middle East North America, 2021-2030 (USD Million)
Table 18.117 Cell Therapy CROs Market in Rest of the World, 2021-2030 (USD Million)
Table 18.118 Cell Therapy CROs Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)
Table 18.119 Gene Therapy CROs Market in North America, 2021-2030 (USD Million)
Table 18.120 Gene Therapy CROs Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Table 18.121 Gene Therapy CROs Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Table 18.122 Gene Therapy CROs Market for Inflammatory Disorders in North America, 2021-2030 (USD Million)
Table 18.123 Gene Therapy CROs Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Table 18.124 Gene Therapy CROs Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Table 18.125 Gene Therapy CROs Market for Clinical Operations in North America, 2021-2030 (USD Million)
Table 18.126 Gene Therapy CROs Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Table 18.127 Gene Therapy CROs Market in Europe, 2021-2030 (USD Million)
Table 18.128 Gene Therapy CROs Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Table 18.129 Gene Therapy CROs Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Table 18.130 Gene Therapy CROs Market for Inflammatory Disorders in Europe, 2021-2030 (USD Million)
Table 18.131 Gene Therapy CROs Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Table 18.132 Gene Therapy CROs Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Table 18.133 Gene Therapy CROs Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Table 18.134 Gene Therapy CROs Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Table 18.135 Gene Therapy CROs Market in Asia-Pacific, 2021-2030 (USD Million)
Table 18.136 Gene Therapy CROs Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.137 Gene Therapy CROs Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.138 Gene Therapy CROs Market for Inflammatory Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.139 Gene Therapy CROs Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 18.140 Gene Therapy CROs Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Table 18.141 Gene Therapy CROs Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 18.142 Gene Therapy CROs Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 18.143 Gene Therapy CROs Market in Latin America, 2021-2030 (USD Million)
Table 18.144 Gene Therapy CROs Market in Middle East North America, 2021-2030 (USD Million)
Table 18.145 Gene Therapy CROs Market: Conservative, Base and Optimistic Scenarios, 2020, 2025 and 2030 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 4Clinics
  2. 4D Molecular Therapeutics
  3. AavantiBio
  4. aaVective
  5. AAVogen
  6. Abeona Therapeutics
  7. Abintus Bio
  8. Absorption Systems
  9. Accelera
  10. AccelLAB
  11. Accelovance
  12. Accord Research
  13. Acer Therapeutics
  14. ACF Bioservices
  15. Activartis Biotech
  16. Adaptimmune
  17. Adicet Bio
  18. Adrenas Therapeutics
  19. Aduro Biotech
  20. Advanced BioScience Laboratories (ABL)
  21. Advanced Cell Diagnostics (ACD)
  22. Advantagene
  23. Advaxis
  24. Adverum Biotechnologies
  25. Affinia Therapeutics
  26. AgenTus Therapeutics
  27. AGINKO Research
  28. AGTC
  29. AIRA Matrix
  30. Akouos
  31. Align Clinical CRO
  32. Allergan
  33. Alliance for Regenerative Medicine (ARM)
  34. Allied Clinical Management
  35. Allife Medical Science and Technology
  36. Allogene Therapeutics
  37. AlphaVax
  38. Altasciences
  39. Altheia Science
  40. Altor BioScience
  41. Amarna Therapeutics
  42. Ambulero
  43. American Gene Technologies™
  44. Amgen
  45. Amicus Therapeutics
  46. Amphera
  47. Amulet Capital Partners
  48. Anaeropharma Science
  49. AnGes
  50. Angionetics
  51. Anhui Kedgene Biotechnology
  52. ANI Pharmaceuticals
  53. apceth Biopharma
  54. ARBELE
  55. Argos Therapeutics
  56. Array Biostatistics (Acquired by CATO SMS)
  57. Aruvant Sciences
  58. ASC Therapeutics
  59. Ascendance Biotechnology
  60. Asklepios BioPharmaceutical (AskBio)
  61. Assistance Publique - Hôpitaux de Paris (AP-HP)
  62. Astellas Pharma
  63. Asterand Bioscience
  64. Asterias Biotherapeutics
  65. AstraZeneca
  66. Atara Biotherapeutics
  67. Athersys
  68. Atreca 
  69. Atsena Therapeutics
  70. Audentes Therapeutics
  71. Aurigon
  72. Aurora Biopharma
  73. Autolus
  74. Avance Biosciences
  75. Avania
  76. AVAX Technologies
  77. AveXis
  78. AVROBIO
  79. Axovant Gene Therapies
  80. Basic Pharma
  81. Baxalta
  82. Baxter
  83. Be The Match BioTherapies
  84. Beam Therapeutics
  85. Beijing Biohealthcare Biotechnology
  86. Beijing Doing Biomedical
  87. Beijing Immunochina Medical Science & Technology
  88. Beijing Sanwater Biological Technology
  89. Beijing Tricision Biotherapeutics 
  90. Beike Biotechnology
  91. Bellicum Pharmaceuticals
  92. BioAccess
  93. BioAgilytix
  94. BioAtla
  95. BioCardia
  96. BioDesk
  97. Biogen
  98. Bioinova
  99. BioIVT
  100. BioMarin Pharmaceutical
  101. Biomere
  102. BioNTech
  103. BioRestorative Therapies
  104. Bio-Techne
  105. Biotect Services
  106. BioVec Pharma
  107. Bioville Clinical (A subsidiary of by Bioville)
  108. bluebird bio
  109. Bone Therapeutics
  110. BrainStorm Cell Therapeutics
  111. BridgeBio
  112. Bristol-Myers Squibb
  113. Caladrius Biosciences
  114. California Institute for Regenerative Medicine (CIRM)
  115. Cambridge Biomedical
  116. Cambridge Gene Therapy
  117. Capricor Therapeutics
  118. Captain T Cell
  119. CardioCell
  120. Carina Biotech
  121. Carmine Therapeutics
  122. CARsgen Therapeutics
  123. CAR-T (Shanghai) Biotechnology
  124. Cartherics
  125. Castle Creek Biosciences
  126. Catalyst Biosciences
  127. CATO SMS
  128. CavoGene LifeSciences
  129. Ce3
  130. Celgene
  131. Celixir
  132. Cell and Gene Therapy Catapult
  133. Cell Biotech
  134. Cell Genesys
  135. Cellectar Biosciences
  136. Cellectis
  137. Cellero
  138. CellGenTech
  139. Cellin Technologies
  140. Cellmed
  141. CellPraxis
  142. CellProtect Nordic Pharmaceuticals
  143. CellProthera
  144. CellTrans
  145. Cellular Biomedicine 
  146. Cellular Therapeutics
  147. Celsion
  148. Celularity
  149. Celyad
  150. CG Oncology
  151. Changhai Hospital
  152. Charles River Laboratories
  153. Chengdu MedGenCell
  154. Chiltern
  155. CiMaas
  156. Cinven
  157. CIRM Alpha Stem Cell Clinic
  158. Citoxlab
  159. City of Hope
  160. Clean Cells
  161. Clinical Network Services (CNS)
  162. Clinscience
  163. Cmed Clinical Services
  164. CMIC
  165. CODA Biotherapeutics
  166. Cogent Biosciences
  167. CombiGene
  168. Comparative Biosciences
  169. Copernicus Therapeutics
  170. Corestem
  171. Covance
  172. CRC Oncology
  173. Creative Biolabs
  174. CRISPR Therapeutics
  175. Crown Bioscience
  176. CSL Behring
  177. CTI Clinical Trial and Consulting Services
  178. Cynvec
  179. Cytopeutics
  180. Cytosen Therapeutics
  181. Cytovac
  182. Cytovation
  183. CyTuVax 
  184. Daiichi Sankyo
  185. DanDrit Biotech
  186. DCPrime
  187. Delta-Vir
  188. Dendreon
  189. Diamond Pharma Services
  190. DiNAQOR
  191. DiscGenics
  192. DNAlite Therapeutics
  193. DNAtrix
  194. Dr. Regenold
  195. Duke University School of Medicine
  196. Editas Medicine
  197. Eli Lilly
  198. Emendo Biotherapeutics
  199. EMMES
  200. Encoded Therapeutics
  201. Endocyte
  202. Endsulin
  203. Enochian BioSciences
  204. Entos Pharmaceuticals
  205. Envigo
  206. Epeius Biotechnologies
  207. Errant Gene Therapeutics
  208. Esteve
  209. Eureka Therapeutics
  210. Eutilex
  211. Ever Union Biotechnology 
  212. Evotec
  213. Excelya
  214. Excision BioTherapeutics
  215. Exegenesis Bio
  216. Experior
  217. Expression Therapeutics
  218. EXUMA Biotech
  219. Eyevensys
  220. Farmacore Biotechnology
  221. Fast-Track Drugs & Biologics
  222. Fate Therapeutics
  223. FerGene
  224. Ferrer Internacional
  225. FGK Clinical Research
  226. Fibrocell Technologies
  227. FIMA
  228. Five Prime Therapeutics
  229. Flash Therapeutics
  230. Flexion Therapeutics
  231. Forge Biologics
  232. Formula Pharmaceuticals
  233. Fortress Biotech
  234. Fosun Kite Biotechnology
  235. Freeline Therapeutics
  236. Frontage Laboratories
  237. Gadeta
  238. Gamida Cell
  239. GC Pharma
  240. Geistek Pharma
  241. Gemini Therapeutics
  242. Gene Therapy Research Institution
  243. GeneCure Biotechnologies
  244. Genelux
  245. GeneMedicine
  246. Genentech
  247. GeneOne Life Science
  248. GeneQuine Biotherapeutics
  249. Generation Bio
  250. Genesis Biotechnology
  251. Genespire
  252. Genethon
  253. GeneWerk
  254. Genexine
  255. GenoSafe
  256. Genprex
  257. GenScript
  258. GenSight Biologics
  259. GenVec 
  260. Genzyme
  261. GigaGen 
  262. GlaxoSmithKline
  263. Global Cell Med
  264. Global Center for Medical Innovation (GCMI)
  265. Glycostem Therapeutics
  266. Gradalis
  267. GRI Bio
  268. Gsap
  269. GSK
  270. Guangzhou Trinomab Biotech
  271. Gyroscope Therapeutics
  272. Handl Therapeutics
  273. Heat Biologics
  274. Hebei Senlang Biotechnology
  275. Helixmith
  276. HemaCare
  277. Hemera Biosciences
  278. HemoGenix
  279. Hemostemix
  280. HengRui YuanZheng Bio-Technology
  281. Herantis Pharma
  282. HILDEBRAND PHARMA CONSULTING
  283. Histocell
  284. Histogenics
  285. Holostem Terapie Avanzate
  286. Homology Medicines
  287. HORAMA
  288. Human Stem Cells Institute PJSC (HSCI)
  289. HuMurine Technologies
  290. Hunan Zhaotai Yongren Biotech
  291. i.e Advising
  292. iCarTAB BioMed
  293. iCell Gene Therapeutics
  294. ICON
  295. ICRC-Weyer
  296. Ikarovec
  297. Ilya Pharma
  298. Imanis Life Sciences
  299. Immatics
  300. Immune Therapeutics
  301. Immunicum
  302. ImmunoCellular Therapeutics
  303. Immunocore
  304. Immunovative Therapies 
  305. Immusoft
  306. Immutep
  307. IMS Health
  308. INC Research
  309. Incysus
  310. Innovative Cellular Therapeutics
  311. Inovio Pharmaceuticals
  312. inRegen
  313. Intellia Therapeutics
  314. InteRNA Technologies
  315. Intertek Pharmaceutical Services
  316. Iovance Biotherapeutics
  317. IPM Biotech
  318. IQVIA
  319. ISTO Technologies
  320. IVERIC bio
  321. Ivy Life Sciences
  322. JAFRAL Biosolutions
  323. Janssen
  324. JSB Solutions
  325. Juno Therapeutics
  326. JW Biotechnology
  327. JW CreaGene
  328. Kadimastem
  329. KAEDI
  330. Kangstem Biotech
  331. Kiadis Pharma
  332. King’s Health Partners
  333. Kiromic
  334. Kite Pharma
  335. Klinar
  336. Kodikaz Therapeutic Solutions
  337. Kolon TissueGene
  338. Kriya Therapeutics
  339. Krystal Biotech
  340. Kubota Vision
  341. Kuopio Center for Gene and Cell Therapy (KCT)
  342. Kuur Therapeutics
  343. KWS BioTest
  344. LabCorp
  345. LatinaBA
  346. Lava Therapeutics
  347. Legend Biotech
  348. Lentistem Biotech
  349. Leucid Bio
  350. LEXEO Therapeutics
  351. Lifecells
  352. Limelight Bio
  353. Lineage Cell Therapeutics
  354. Linical
  355. Linical Accelovance
  356. Lion TCR
  357. Living Pharma
  358. LMC Manna Research
  359. LogicBio Therapeutics
  360. Lokon Pharma
  361. Longeveron
  362. Longmore 60 Biotech
  363. Lovelace Biomedical
  364. Lumos Pharma
  365. Lyell Immunopharma
  366. Lysogene
  367. Magenta Therapeutics
  368. Marino Biotechnology
  369. MaxCyte 
  370. Medelis
  371. Medeor Therapeutics
  372. Medidee
  373. Medigene
  374. MEDINET
  375. MeDiNova Research
  376. MEDIPOST
  377. Medpace
  378. MedVax Technologies
  379. MeiraGTx
  380. Memorial Sloan Kettering Cancer Center
  381. Merck Serono
  382. Mesoblast
  383. MetabAxis
  384. MI Bioresearch
  385. Milo Biotechnology
  386. Minovia Therapeutics
  387. Mitsubishi Tanabe Pharma
  388. MolecuVax
  389. Momotaro-Gene
  390. Moraga Biotechnology
  391. MPI Research
  392. Multimmune
  393. MultiVir
  394. Mustang Bio
  395. Myosana Therapeutics
  396. NantKwest
  397. National Cancer Institute
  398. Navega Therapeutics
  399. Neopharm
  400. Nerviano Medical Sciences (NMS)
  401. NetValue BioConsulting
  402. NeuExcell Therapeutics
  403. Neuracle Genetics
  404. Neuralstem
  405. Neurogene
  406. Neurophth Therapeutics
  407. Ninevah Therapeutics
  408. Nkarta
  409. Noble Life Sciences
  410. Noga Therapeutics
  411. Nohla Therapeutics
  412. Noile-Immune Biotech
  413. Northern Therapeutics
  414. Northwest Biotherapeutics
  415. Novadip Biosciences
  416. Novartis
  417. Novartis Gene Therapies
  418. NovaRx (Acquired by Viropro)
  419. NovaTrials
  420. Novella Clinical
  421. Novotech
  422. Nuo Therapeutics
  423. Nuventra Pharma Sciences
  424. Ocugen
  425. OhioHealth
  426. OiDE BetaRevive
  427. OncoBay Clinical
  428. Oncobiomed
  429. Oncolys BioPharma
  430. Onconetics Pharmaceuticals
  431. OncoSec
  432. OncoSenX
  433. Opexa Therapeutics
  434. ORCA Therapeutics
  435. Orchard Therapeutics
  436. Osiris Therapeutics
  437. Oxford BioMedica
  438. Oxular
  439. Passage Bio
  440. PathoQuest
  441. Pattern BioScience
  442. PDC*line Pharma
  443. PeriphaGen
  444. PersonGen BioTherapeutics
  445. Pfizer
  446. PHArmaceutical Research Management (PHARM)
  447. Pharmacia
  448. Pharmahungary
  449. PharmaLex
  450. Pharmaron
  451. Pharmaseed
  452. Pharmicell
  453. Phoenix Nest
  454. PhorMed
  455. Pilgrim Quality Solutions
  456. Pinze Lifetechnology
  457. Pique Therapeutics
  458. Pluristem Therapeutics
  459. Plus Therapeutics
  460. Poseida Therapeutics
  461. PPD
  462. PRA Health Sciences
  463. PRC Clinical
  464. Precigen
  465. Precision BioSciences
  466. Precision Medicine
  467. Pregene ShenZhen Biotechnology
  468. Prevail Therapeutics
  469. Promethera Biosciences
  470. PSI CRO
  471. PsiOxus Therapeutics
  472. PSNResearch
  473. PTC Therapeutics
  474. QPS
  475. Q-Trials
  476. Quality Assistance
  477. Quality by Design (QbD)
  478. Radyus Research
  479. Redbiotec
  480. Redpin Therapeutics
  481. Regeneris Medical
  482. Regeneron
  483. Regeneus
  484. REGENXBIO
  485. ReNeuron
  486. Renova Therapeutics
  487. Research Dynamics Consulting Group
  488. Rexgenero
  489. RHEACELL
  490. Ring Therapeutics
  491. Rocket Pharmaceuticals
  492. Rubius Therapeutics
  493. Sangamo Therapeutics
  494. Sanofi
  495. Sarah Cannon Development Innovations
  496. Sarepta Therapeutics
  497. Saronic Biotechnology
  498. SBH Sciences
  499. Scancell
  500. SCiAN Services
  501. Sciformix
  502. Sclnow Biotechnology
  503. Scope International
  504. SCRO
  505. Seattle Genetics
  506. Selecta Biosciences
  507. Sentien Biotechnologies
  508. Sermes CRO
  509. Sernova
  510. Servier
  511. Shanghai Bioray Laboratory
  512. Shanghai GeneChem
  513. Shanghai Houchao Biotechnology
  514. Shanghai iCELL Biotechnology
  515. Shanghai Longyao Biotechnology
  516. Shanghai Sunway Biotech
  517. Shanghai Unicar-Therapy Bio-medicine Technology
  518. Shenzhen BinDeBio
  519. Shenzhen Hornetcorn Biotechnology
  520. Shionogi
  521. Sibiono GeneTech
  522. SillaJen
  523. Sinobioway Cell Therapy
  524. SMT Bio
  525. SNBL USA
  526. Society for Clinical Research Sites
  527. Solid Biosciences
  528. Sorrento Therapeutics
  529. SOTIO
  530. Spark Therapeutics
  531. Spectralys Biotech
  532. Spirovant Sciences
  533. SQZ Biotechnologies
  534. SR-Tiget
  535. St. Jude Children’s Research Hospital
  536. Stem Cell Arabia
  537. Strategic Preclinical Product Development (S2PD)
  538. StrideBio
  539. Sumitomo Dainippon Pharma
  540. Super-T Cell Cancer Company
  541. Surface Oncology
  542. SUSMED
  543. Svar Life Science
  544. SwanBio Therapeutics
  545. Symbion Research International
  546. Symphony Clinical Research
  547. Syneos Health
  548. Synteract
  549. Taconic Biosciences
  550. Tactiva Therapeutics
  551. Taiwan Bio Therapeutics
  552. Takara Bio
  553. Takeda
  554. Takeda Pharmaceutical
  555. TapImmune 
  556. Targazyme
  557. Targovax
  558. Taysha Gene Therapies
  559. TC BioPharm
  560. TCR2 Therapeutics
  561. TCTC Group
  562. TechnoPharmaSphere
  563. Tella
  564. Tenaya Therapeutics
  565. Tessa Therapeutics
  566. TFS HealthScience
  567. The Cell Factory
  568. The Discovery Labs
  569. TheraBiologics
  570. Theradex Oncology
  571. Theravectys
  572. ThermoGenesis
  573. Tianhe Stem Cell Biotechnologies
  574. TiGenix (Acquired by Takeda Pharmaceutical)
  575. TILT Biotherapeutics
  576. Tmunity Therapeutics
  577. TNK Therapeutics
  578. Tolerion
  579. TotipotentRX
  580. TRACT Therapeutics
  581. TransCell Science
  582. TransCure bioServices
  583. Transgene
  584. Translational Drug Development (TD2)
  585. Triumvira Immunologics
  586. Trizell
  587. Trucode Gene Repair
  588. TVAX Biomedical
  589. Ultragenyx Pharmaceutical
  590. Unilabs
  591. uniQure Biopharma
  592. United BioSource (UBC)
  593. Universal Cells
  594. Universitat Autònoma de Barcelona (UAB)
  595. University of Colorado
  596. University of Pennsylvania
  597. Urovant Sciences
  598. US Stem Cell
  599. Vaccinogen
  600. VBL Therapeutics
  601. VCN Biosciences
  602. Veeva Systems
  603. Vericel
  604. Veristat
  605. Verve Therapeutics
  606. ViGeneron
  607. ViroMed
  608. Viscofan BioEngineering
  609. Vivet Therapeutics
  610. Vivotecnia
  611. Voyager Therapeutics
  612. VREX Therapeutics
  613. Wake Forest Innovations
  614. WCCT Global
  615. WIRB-Copernicus Group (WCG)
  616. WiSP Wissenschaftlicher Service Pharma
  617. Wize Pharma
  618. Worldwide Clinical Trials
  619. Wuhan Sian Medical Technology
  620. WuXi AppTec
  621. Wyvern Pharmaceuticals
  622. Xcelthera
  623. XEME Biopharma
  624. XyloCor Therapeutics
  625. Zelluna Immunotherapy 
  626. Zentiva
  627. Zimmer Biomet
  628. Ziopharm Oncology

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com